Evidence map›Paper›PMID 40297307›Full record

ReviewGut microbiome (Cambridge, England)2025

Association of

Luana Greco, Federica Rubbino, Clarissa Ferrari, Michela Cameletti, Fabio Grizzi, Fabrizio Bonelli, Alberto Malesci, Massimiliano Mazzone, Luigi Ricciardiello, Luigi Laghi

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Gut microbiome (Cambridge, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Impact ofFrontiers in immunology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Luana GrecoLaboratory of Molecular Gastroenterology, IRCCS Humanitas Research Hospital, Milan, Italy.ORCID https://orcid.org/0000-0002-6507-3257
Federica RubbinoLaboratory of Molecular Gastroenterology, IRCCS Humanitas Research Hospital, Milan, Italy.
Clarissa FerrariResearch and Clinical Trials Office, Fondazione Poliambulanza Istituto Ospedaliero, Brescia, Italy.
Michela CamelettiDepartment of Economics, University of Bergamo, Bergamo, Italy.
Fabio GrizziDepartment of Biomedical Sciences, Humanitas University, Milan, Italy.
Fabrizio BonelliDiaSorin SpA, Saluggia, Italy.
Alberto MalesciUniversità Vita-Salute San Raffaele, Milan, Italy.
Massimiliano MazzoneDepartment of Biomedical Sciences, Humanitas University, Milan, Italy.
Luigi RicciardielloDepartment of Gastroenterology, Hepatology and Nutrition, The University of Texas at MD Anderson Cancer Center, Houston, TX, USA.
Luigi LaghiLaboratory of Molecular Gastroenterology, IRCCS Humanitas Research Hospital, Milan, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer (CRC) represents a relevant public health problem, with high incidence and mortality in Western countries. CRC can occur as sporadic (65%-75%), common familial (25%), or as a consequence of an inherited predisposition (up to 10%). While unravelling its genetic basis has been a long trip leading to relevant clinical implementation over more than 30 years, other contributing factors remain to be clarified. Among these, micro-organisms have emerged as critical players in the development and progression of the disease, as well as for CRC treatment response.

Indexed as

colorectal cancerFusobacterium nucleatummicrobiomeprognosis

Identifiers

PMID40297307
PMCPMC12035788

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.